You are here: Industry Insights > NICE

News List

NICE recommends Sanofi’s Gaucher treatment pharmaphorum
June 29, 2017
England’s NHS will routinely fund Sanofi/Genzyme’s Cerdelga (eliglustat) for the rare condition Gaucher disease after a recommendation from NICE.
NICE turnaround for AstraZeneca’s COPD drug Daxas pharmatimes
June 26, 2017
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug offers value for money in this setting.
NICE rejects Pfizer’s ALL drug Besponsa pharmatimes
June 15, 2017
to treat some patients with leukaemia on the NHS in England and Wales.
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma europeanpharmaceuticalreview
June 15, 2017
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
NICE recommends Janssen's first-of-its-kind Crohn's drug Stelara pharmafile
May 04, 2017
Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the...
NICE nod for Amgen’s rare leukaemia drug pharmatimes
May 04, 2017
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England...
NICE recommends Janssen’s Crohn’s Disease biological therapy europeanpharmaceuticalreview
May 03, 2017
The National Institute for Health and Care Excellence (NICE) has recommended Janssen‘s Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with moderately to severely active Crohn’s disease.
NICE backs new option for Crohn’s disease pharmatimes
May 02, 2017
The National Institute for Health and Care Excellence is backing the use of Janssen’s biologic Stelara to treat adult...
NICE recommends Ixekizumab (Taltz) to treat severe plaque psoriasis pharmaceutical-technology
April 28, 2017
Eli Lilly and Company has announced that UK NICE has recommended the usage of Ixekizumab (Taltz) as an option...
Takeda’s Ninlaro rejected by NICE for multiple myeloma pharmatimes
April 28, 2017
Takeda has vowed to work with the National Institute for Health and Care Excellence to get NHS funding approved for its ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page